article thumbnail

Orbital raises $270m investment for advancement of RNA medicines

Pharmaceutical Technology

Orbital Therapeutics has raised $270m in a Series A round led by ARCH Venture Partners to advance a portfolio of programmable RNA therapeutics. Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement.

RNA 130
article thumbnail

RNA holds the reins in bacteria: U-M researchers observe RNA controlling protein synthesis

Scienmag

Credit: Surajit Chatterjee To better understand how RNA in bacteria gives rise to protein–and along the way, target these processes in the design of new antibiotics–researchers are turning their attention to the unique way this process happens in bacteria.

RNA 82
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ORI Capital, the venture firm behind CG’s big IPO, raises new biotech fund

Bio Pharma Dive

The $260 million fund will be used to back startups working on new drugmaking approaches like protein degraders and RNA therapies.

RNA 177
article thumbnail

Potential drug target for difficult-to-treat breast cancer: RNA-binding proteins

Scienmag

Studies using human cell lines and tumors grown in mice provide early evidence that inhibiting RNA-binding proteins, a previously overlooked family of molecules, might provide a new approach for treating some cancers Credit: UC San Diego Health Sciences In cancer research, it’s a common goal to find something about cancer cells — some sort (..)

RNA 87
article thumbnail

RNA editing protein ADAR1 protects telomeres and supports proliferation in cancer cells

Scienmag

Credit: The Wistar Institute PHILADELPHIA — (March 12, 2021) — Scientists at The Wistar Institute identified a new function of ADAR1, a protein responsible for RNA editing, discovering that the ADAR1p110 isoform regulates genome […].

RNA 92
article thumbnail

Moderna reports ‘encouraging’ early data for one of its rare disease medicines

Bio Pharma Dive

The biotech, best known for its vaccine research, said its clinical trial is the first to report results of a messenger RNA therapeutic designed for intracellular protein replacement.

RNA 294
article thumbnail

Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal

pharmaphorum

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . The post Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal appeared first on.

RNA 74